Cryoport, Inc. reported financial results for the second quarter ended June 30, 2026, announcing total revenue of $49.0 million, an 8% increase year-over-year. Life Sciences Services revenue grew 15% to $27.97 million, while Life Sciences Products revenue remained flat at $21.0 million. The company achieved positive adjusted EBITDA from continuing operations of $0.4 million for the quarter, marking a milestone in its pathway to profitability. Net loss attributable to common stockholders was $10.3 million, or $0.20 per share, compared to net income of $106.9 million in the prior year period driven by discontinued operations. As of June 30, 2026, Cryoport supported 779 global clinical trials and 22 commercially approved cell and gene therapies. The company operates as a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences.

At its 2026 Annual Meeting of Stockholders on June 5, 2026, Cryoport, Inc. approved an amendment to the 2018 Omnibus Equity Incentive Plan to increase the number of authorized shares. Stockholders also elected six directors, ratified Deloitte and Touche LLP as the independent registered public accounting firm for 2026, and approved the advisory vote on executive compensation. The company provides specialized cryogenic logistics and supply chain solutions for the life sciences industry.